Here, we explore the potential mechanisms through which IQGAP1 influences metabolic disorders, with a focus on its regulation of key metabolic pathways and its implications in diseases such as diabetes, obesity, cardiovascular disease, non-alcoholic fatty liver disease (NAFLD), and osteoporosis. This evidence concerns the gene IQGAP1 and metabolic dysfunction-associated steatotic liver disease.